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What’s new? 
 The Diabetes Prevention Outcomes Study (DPPOS) is the largest global trial to date 
aimed at preventing or delaying diabetes onset in a high-risk group. 
 We have retained ~ 85% of the original participants for nearly 20 years. 
 At the time of the most recent data lock, ~ 50% of participants had developed 
diabetes, whereas the others had not. This analysis examines residual risk factors for 
diabetes and microvascular disease not formerly explored in the DPPOS. 
 Simple clinical information, such as the number of medications taken and glycaemic 
variability, are associated with increased risk for diabetes and microvascular disease. 
 Hypertension and use of anti-hypertensive medication predicted composite 
microvascular disease independent of diabetes status. 
 
Abstract 
Aim Approximately half of the participants in the Diabetes Prevention Outcomes Study 
(DPPOS) had diabetes after 15 years of follow-up, whereas nearly all the others remained 
with pre-diabetes. We examined whether formerly unexplored factors in the DPPOS 
coexisted with known risk factors that posed additional risk for, or protection from, diabetes 
as well as microvascular disease. 
Methods Cox proportional hazard models were used to examine predictors of diabetes. 
Sequential modelling procedures considered known and formerly unexplored factors. We 
also constructed models to determine whether the same unexplored factors that associated 
with progression to diabetes also predicted the prevalence of microvascular disease. Hazard 
ratios (HR) are per standard deviation change in the variable. 
Results In models adjusted for demographics and known diabetes risk factors, two formerly 
unknown factors were associated with risk for both diabetes and microvascular disease: 
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number of medications taken (HR = 1.07, 95% confidence intervals (95% CI) 1.03 to 1.12 for 
diabetes; odds ratio (OR) = 1.10, 95% CI 1.04 to 1.16 for microvascular disease) and 
variability in HbA1c (HR = 1.02, 95% CI 1.01 to 1.03 for diabetes; OR = 1.06, 95% CI 1.04 
to 1.09 for microvascular disease per SD). Total comorbidities increased risk for diabetes 
(HR = 1.10, 95% CI 1.04 to 1.16), whereas higher systolic (OR = 1.22, 95% CI 1.13 to 1.31) 
and diastolic (OR = 1.14, 95% CI 1.05 to 1.22) blood pressure, as well as the use of anti-
hypertensives (OR = 1.41, 95% CI 1.23 to 1.62), increased risk of microvascular disease. 
Conclusions Several formerly unexplored factors in the DPPOS predicted additional risk for 
diabetes and/or microvascular disease – particularly hypertension and the use of anti-
hypertensive medications – helping to explain some of the residual disease risk in participants 
of the DPPOS. (Clinical Trial Registry Nos: DPP NCT00004992 and DPPOS NCT00038727) 
 
Introduction 
To date, the Diabetes Prevention Program (DPP) is the largest clinical trial in the world 
designed to determine whether an intensive lifestyle intervention or metformin could prevent 
or delay the onset of Type 2 diabetes in a high-risk multi-ethnic cohort [1]. Of the 3234 
original participants in the DPP, 85% continue to be followed in the Diabetes Prevention 
Program Outcomes Study (DPPOS), 14–17 years post randomization at 10 July 2013, the 
closing date of this analysis. Approximately half the participants had developed diabetes and 
nearly all the others continued to have pre-diabetes, as they did from initial enrolment. The 
annual incidence rate of diabetes has decreased in all groups and has not differed significantly 
between the intervention groups in recent years, presumably due to depletion of susceptible 
individuals [2]. Thus, many participants have had persistent pre-diabetes, without the 
development of overt diabetes, over the past 15 years of study. This is the case despite the 
presence of significant baseline risk for progression based on traditional diabetes risk factors 
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(e.g. obesity, elevated fasting glucose, impaired glucose tolerance). The observation that 
nearly half remained free of diabetes despite the presence of substantive clinical risk raises 
the possibility that residual factors coexist with known risk factors that collectively protect 
from or exaggerate risk for diabetes. Identification of these formerly unexplored factors could 
aid with risk stratification, and thereby improve decision-making in the setting where 
resources are being directed toward prevention. 
Active treatment during DPP resulted in rapidly apparent, persistent treatment-specific effects 
to prevent or delay diabetes [1,3], and the prevention/delay of diabetes was associated with a 
lower prevalence of microvascular disease 14–17 years post randomization [4]. Surprisingly, 
the treatment-specific differences in rates of diabetes have not produced corresponding 
differences in the overall prevalence of microvascular disease to date, with the exception that 
among women only, the prevalence of microvascular disease was lower in the intensive 
lifestyle group [4]. This observation has been ascribed to the minimal degree of 
hyperglycaemia experienced to date among most DPPOS participants who developed 
diabetes [4]. It may also suggest that the interventions used in the DPP, although effective at 
minimizing glycaemia, have been insufficient to mitigate important non-glycaemic 
determinants of microvascular disease, such as habitual diet or social factors. The possibility 
that non-glycaemic biomarkers could inform us about risk, for both diabetes and related 
complications, needs further elucidation. 
Only part of the risk for diabetes [5], and the risk for microvascular [6] and macrovascular [7] 
complications associated with diabetes is explained by known risk factors. This gap in the 
current knowledge led to a search for residual factors with diabetogenic or anti-diabetogenic 
potential. The objective of the current analysis was to examine the effects of factors formerly 
unexplored in the DPP to reduce or augment risk for diabetes and/or microvascular disease in 
this high-risk cohort. We hypothesized that formerly unexplored factors may be protective, 
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rendering a state of non-progressive pre-diabetes with a lower cumulative glycaemic 
exposure and lower risk for microvascular disease. 
 
Patients and methods 
Participants 
The DPP was a randomized clinical trial performed at 27 research centres in the USA that 
enrolled overweight or obese adults with pre-diabetes determined on one occasion. BMI 
≥ 24 kg/m2 (≥ 22 kg/m2 in Asian Americans), elevated fasting glucose 95–125 mg/dl (5.3–
6.9 mmol/l; < 6.9 mmol/l in the American Indian Centers) and 2-h plasma glucose levels of 
140–199 mg/dl (7.8–11.0 mmol/l) were eligibility criteria. The DPPOS is the follow-up to the 
DPP and includes 2775 people (85% of the original cohort at the data lock on 10 July 2013). 
Detailed methods have been published previously [8] and the protocol is available at 
http://www.bsc.gwu.edu/dpp. Institutional review boards at each centre approved the 
protocol, and all participants gave written informed consent prior to participation. 
 
Interventions 
During the DPP, participants were randomized to: (1) an intensive lifestyle intervention (low-
fat diet and exercise > 150 min/week for a goal of 7% body weight reduction); (2) metformin 
850 mg twice daily; or (3) matching placebo (Fig. 1). Median follow-up during the DPP was 
3.2 years followed by a 10-month ‘bridge’ period when all participants were offered group-
implemented lifestyle sessions prior to the start of DPPOS, including those who had been 
randomized to the intensive lifestyle arm during DPP [3]. Open-label metformin was also 
continued in participants initially randomized to metformin during DPP, and discontinued 
when progression to diabetes required management outside the protocol, or for reasons of 
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safety and/or tolerability. Median follow-up in the DPPOS was 15 years from randomization 
to the closing date of this analysis (10 July 2013; range 14–17 years). 
 
Outcomes 
The primary outcome of the DPP and DPPOS is the development of diabetes, defined as a 
fasting plasma glucose ≥ 126 mg/dl (≥ 7.0 mmol/l; tested twice a year) and/or 2-h glucose 
≥ 200 mg/dl (≥ 11.1 mmol/l; tested annually) during a 75-g oral glucose tolerance test 
(OGTT). Once diabetes is confirmed on a second test, the participant is classified as having 
diabetes regardless of subsequent plasma glucose values. Persistent normoglycaemia is 
defined as fasting plasma glucose levels of < 100 mg/dl (5.6 mmol/l) and 2-h plasma glucose 
levels of < 140 mg/dl (7.8 mmol/l) on every annual OGTT after enrolment. Persistent pre-
diabetes [9] is defined as fasting plasma glucose levels of 100–125 mg/dl (5.6–6.9 mmol/l), 
2-h plasma glucose levels of 140–199 mg/dl (7.8–11.0 mmol/l), or both on an OGTT at 
baseline and at least once thereafter, but not developing diabetes and not achieving persistent 
normoglycaemia during follow-up. Approximately 50% of participants achieved 
normoglycaemia at some time during the trial [10], however, its persistence was uncommon. 
To focus on predictors of diabetes vs. persistent pre-diabetes, 45 participants (1.4%) who 
achieved and maintained normoglycaemia throughout the DPP and DPPOS were excluded 
from the present analysis. Predictors of normoglycaemia and its protection from diabetes 
have been reported previously [10,11]. 
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Development of microvascular disease is a co-primary outcome of DPPOS 
Microvascular disease was defined as follows: 
 retinopathy; diagnosed on 7-field stereoscopic fundus photography by the Early 
Treatment of Diabetic Retinopathy Study (ETDRS) as ≥ 20 in either eye, or treatment 
of retinopathy with laser photocoagulation or intravitreal injections, assessed during 
the DPPOS in 2012 or 2013; 
 neuropathy; defined as loss of light touch sensation (< 8 of 10 applications detected 
on the dorsum of the great toe) measured with a 10-gram Semmes–Weinstein 
monofilament [12], assessed annually throughout DPPOS; and/or 
 nephropathy; assessed by albuminuria ≥ 30 mg/g creatinine in a spot urine collection 
on two consecutive tests, or an eGFR < 45 ml/min/1.73 m
2
, based on annual serum 
creatinine using the CKD-EPI equation
 
[13] on two consecutive tests, or renal failure 
(end-stage renal disease, dialysis or transplantation, assessed annually throughout the 
DPPOS). Participants taking antihypertensive drugs at the final assessment who did 
not meet albuminuria or estimated GFR criteria at that time were considered to have 
reached the nephropathy outcome if the nephropathy criteria were met at two 
consecutive prior visits. 
 
Predictors of interest 
We examined the influence of formerly unexplored factors in the DPPOS in the context of 
factors that have been shown as related to diabetes in the DPP and/or DPPOS. A complete list 
of all predictors explored, their measurement interval(s) and method of derivation are 
presented in Table 1. Quality of life used the composite score from the SF6D, a truncated 
version of the SF-36 Health Survey Questionnaire [14]. Values were taken from the baseline 
of the DPP, with the exception of time-varying change in the major predictors of diabetes in 
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the DPP and/or DPPOS (variability in weight, i.e. standard deviation in weight over the DPP 
and DPPOS, regression to normal glucose regulation (NGR; defined during DPP) and 
variability in HbA1c, i.e. root mean square HbA1c over DPP and DPPOS). The baseline 
characteristics of the randomized cohort have been published previously [15]. 
 
Statistical analyses 
Selected factors were examined for their prediction of diabetes and microvascular disease 
(Table 1). Univariate Cox proportional hazards regression models were constructed for each 
potential predictor and adjusted for age, sex and race/ethnicity, and DPP treatment arm 
(model 1). The subsequent multivariable model (model 2) adjusted model 1 for factors 
formerly shown to predict diabetes in the DPP (baseline fasting and 2-h plasma glucose, 
insulin secretion and sensitivity, BMI, history of gestational diabetes, use of antidepressants 
and plasma adiponectin concentration, as well as time-varying BMI, HbA1c and regression to 
NGR). Hazard ratios (HRs) in these models represent the comparison of a categorical 
variable to its reference category, or per standard deviation difference in a continuous 
variable. We applied a parallel approach to evaluate the association of the candidate 
prognostic factors with microvascular disease, applying logistic regression rather than Cox 
proportional hazards modelling because composite microvascular disease prevalence data 
were available at only one point in time. Duration of diabetes was also included as a covariate 
for model 2 predicting microvascular disease. The model building procedure used to derive 
models 1 and 2 (above) was repeated to examine the predictive value of candidate factors on 
prevalence of nephropathy, neuropathy and retinopathy, as well as the composite 
microvascular complication outcome (i.e. one or more of these complications), occurring at a 
median time of 15 years since initial enrolment in the DPP. Using the methods of Bonferroni, 
a P-value of ≤ 0.002 was used to denote significance accounting for multiple comparisons. 
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Thus, the 95% confidence intervals (95% CI) may not cross 1.0 and still be considered not 
significant. 
 
Results 
By 10 July 2013, diabetes had been diagnosed in 50.4% of participants, 48.2% had pre-
diabetes (without ever meeting the diagnosis of diabetes), and 1.4% returned and remained 
normoglycaemic (the latter were excluded from this analysis; see above). Those with 
persistent pre-diabetes had plasma glucose values consistent with the diagnostic thresholds 
for pre-diabetes 77% of the time (vs. 93% in those who progressed to diabetes) and 
normoglycaemia 23% of the time (vs. 7% in those who progressed to diabetes). 
 
Formerly unexplored predictors of diabetes and microvascular disease in the DPPOS 
In fully adjusted models (model 2), two formerly unidentified factors were associated with 
risk for both diabetes and microvascular disease: greater number of medications taken 
(HR = 1.03, 95% CI 1.03 to 1.12 for diabetes; odds ratio (OR) = 1.10, 95% CI 1.04 to 1.16 
for microvascular disease) and variability in HbA1c (HR = 1.02, 95% CI 1.01 to 1.03 for 
diabetes; OR = 1.06, 95% CI 1.04 to 1.09 for microvascular disease). The most common 
types of medication reported were hormones (oral contraceptives or post-menopausal 
hormone therapy) and anti-hypertensives, accounting for 24.8% and 17.7% respectively, of 
the total medications reported. We performed a sensitivity analysis to determine whether the 
use of anti-hypertensive medication explained the association between total medications 
reported and diabetes and microvascular disease. After omission of anti-hypertensive drugs, 
numbers of medications taken were no longer significantly related to diabetes (HR = 1.07, 
95% CI 1.02 to 1.11) or microvascular disease (OR = 1.06, 95% CI 0.99 to 1.13). Anti-
hypertensive use was associated with microvascular disease (OR = 1.41, 95% CI 1.23 to 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
1.62), independent of blood pressure, with a similar trend seen for diabetes (OR = 1.17, 95% 
CI 1.05 to 1.31). 
 
Formerly unexplored predictors of diabetes or microvascular disease, but not both, in 
the DPPOS 
Total comorbidities increased risk for diabetes (HR = 1.10, 95% CI 1.04 to 1.16) with a 
similar trend observed for microvascular disease (OR = 1.12, 95% CI 1.04 to 1.20). Greater 
time varying triglyceride (TG)/HDL ratio predicted diabetes and microvascular disease in 
model 1, but not in model 2 (Table 2). Both systolic (OR = 1.22, 95% CI 1.13 to 1.31) and 
diastolic (OR = 1.14, 95% CI 1.05 to 1.22) blood pressure were associated with an increased 
risk of microvascular disease, whereas systolic blood pressure alone was associated with 
diabetes in model 1 (OR = 1.12, 95% CI 1.07 to 1.18). Higher quality of life appeared to 
protect against diabetes in the univariate model, but failed to maintain significance in the 
multivariable model. 
 
Formerly unexplored predictors of retinopathy, nephropathy and/or neuropathy in the 
DPPOS 
To account for differences in ascertainment intervals, mixed models were used to estimate 
prevalence of retinopathy (11%), nephropathy (14%) and neuropathy (12%). Greater number 
of comorbidities reported (OR = 1.23, 95% CI 1.10 to 1.38; OR = 1.19), associated with 
nephropathy, in the fully adjusted model, as observed with diabetes and composite 
microvascular disease. As with composite microvascular disease, the relationships between 
the subtypes of microvascular disease and numbers of medications reported did not retain 
significance after omission of anti-hypertensive medications (OR = 0.94, 95% CI 0.78 to 1.13 
for nephropathy; OR = 0.91, 95% CI 0.71 to 1.17 for retinopathy; OR = 1.20, 95% CI 0.95 to 
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1.52, P = 0.12 for neuropathy). Variability in HbA1c was the only formerly unexplored factor 
that associated with retinopathy after full adjustment (OR = 1.09, 95% CI 1.04 to 1.14). Both 
systolic (OR = 1.47, 95% CI 1.30 to 1.65) and diastolic (OR = 1.31, 95% CI 1.17 to 1.48) 
blood pressure associated with an increased risk for nephropathy, as they did for composite 
microvascular disease. The associations between quality of life, household income and 
weight variability with neuropathy were only observed in the univariate model. 
A subset of these known and formerly explored factors and their association with the various 
outcomes in the DPPOS are shown in Table 2. Data for all the selected variables on the 
outcomes are shown in univariate and multivariate models in Tables S1–S6. 
 
Discussion 
Approximately half of participants in the DPPOS have persistent pre-diabetes since their 
enrolment over 15 years ago. We sought to determine whether protective factors coexisted 
with known risk factors to retard development of overt diabetes and/or microvascular disease, 
or, alternatively, if formerly unidentified novel risk factors compounded known risk in those 
who developed diabetes and/or microvascular disease. Major findings from the current 
analyses suggest that the number of medications taken, as well as variability in HbA1c, 
proved to be formerly unidentified predictors of both diabetes and microvascular disease in 
the DPPOS. Hypertension and the use of anti-hypertensive medications appeared particularly 
relevant to microvascular disease, but far less so to diabetes. Collectively, formerly 
unexplored factors appear to provide additional information for the prediction of 
microvascular disease rather than diabetes in our well-described DPPOS cohort. 
As momentum builds in support of widespread preventive interventions in people with pre-
diabetes [16–18], important counter-arguments must be addressed. Yudkin and Montori 
wrote a recent counterpoint to the medicalization of pre-diabetes [19], citing over-diagnosis 
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by current criteria and unnecessary treatment for the ~ 50% of people with pre-diabetes never 
destined to develop diabetes. Data from the Baltimore Longitudinal Study of Aging suggest 
that two-thirds of people with pre-diabetes will either spontaneously regress or remain with 
pre-diabetes for long durations, leaving only the remaining one-third at risk for diabetes itself 
[20]. In diabetes prevention studies, including the DPP, diabetes risk is determined primarily 
by elevated plasma glucose levels (fasting and/or post-OGTT). Current findings highlight the 
deficiencies of this approach and indicate a clear need for risk stratification beyond 
glycaemia. In the present analysis, we demonstrate higher incidences of both diabetes and 
microvascular disease in participants who reported a greater number of medications taken 
from the outset of the DPP, with only two medications needed to go from the 25th to the 75th 
percentile for risk (data not shown). This was particularly relevant when participants reported 
using anti-hypertensives. In addition, variability in HbA1c (as a measure of glycaemic 
variability [21]) over time, also appeared to influence risk for diabetes and microvascular 
disease beyond traditional risk factors. Ongoing clinical trials hope to prove this point [22,23] 
making both the absolute HbA1c and glycaemic variability relevant to patient care. Collection 
of this basic historical and laboratory information, which is already performed routinely , 
may improve our risk assessment for people with pre-diabetes where access to other 
information is limited. 
In pursuit of novel risk-conferring or protective factors for diabetes and microvascular 
disease, some factors exhibited discordance associating with one or the other, but not both. 
Total comorbidities increased the risk for diabetes with a similar trend observed for 
microvascular disease. Given the close correlation between numbers of medications taken 
and numbers of comorbidities reported, this information likely reflects overall health status 
and deserves greater appreciation as a metric of health risk [24]. By contrast, both SBP and 
DBP increased the risk of microvascular disease with little association with diabetes. 
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Although hypertension is widely recognized as a risk factor for microvascular disease and 
cardiovascular disease [25,26], this is the first report of these associations in the DPPOS. 
Importantly, these results highlight the risk for microvascular disease associated with 
hypertension that may precede the onset of diabetes [27]. Accordingly, the management of 
hypertension remains central in the prevention of both micro- and macrovascular disease. 
The DPPOS used a composite microvascular disease outcome as its primary endpoint for 
long-term complications [4], in part, with the expectation of a shared mechanism for 
retinopathy, nephropathy and neuropathy [28]. Although greater number of comorbidities 
reported and variability in HbA1c associated with both diabetes and composite microvascular 
disease, they did not associate uniformly with each individual microvascular disease subtype. 
Specifically, a greater number of comorbidities reported predicted nephropathy, whereas 
variability in HbA1c predicted retinopathy, in the fully adjusted models. The latter 
observation is consistent with the highly specific association between retinopathy and plasma 
glucose concentration [29,30]. By contrast, hypertension appeared specific to nephropathy. 
Together, these preliminary post hoc results cast a degree of uncertainty on the prevailing 
paradigm that development of microvascular disease is relatively homogenous [28]. 
Expanding our knowledge of the pathogenesis of microvascular diseases will likely lead to 
new approaches to prevent them. 
Several limitations of our analysis warrant mention. This analysis is post hoc and the results 
can be viewed as hypothesis generating. Associations do not confirm causation. Thus far, 
rates of complications, especially for the individual components of microvascular disease, 
have been very low and different ascertainment schedules, as well as the sensitivity of our 
methods of detection, for the microvascular disease endpoints complicate direct comparisons 
of individual microvascular disease outcomes. 
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In conclusion, the current analysis highlights several formerly unexplored factors that 
associate with risk for diabetes, but did not heighten our understanding as to why 
approximately half of our high-risk cohort has developed diabetes since enrolment into DPP, 
whereas the other half has not. Several of these factors predicted composite microvascular 
disease, whereas some were associated with either diabetes or microvascular disease, but 
collectively only improved prediction for microvascular disease. Importantly, our findings 
were comprised of basic information (e.g. use of blood pressure lowering medication) 
routinely collected in a clinical setting providing additional information about who may be at 
risk for the complications of diabetes. 
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FIGURE 1 CONSORT diagram (adapted from American Diabetes Association. Diagnosis and classification of 
diabetes mellitus. Diabetes Care 2004; 27(Suppl 1): S5–S10). DPP, Diabetes Prevention Program; DPPOS, 
Diabetes Prevention Program Outcomes Study. *The DPP enrolled participants over a 3-year period ending June 
1999, therefore participants had varying duration of DPP follow-up depending on their year of enrolment. †DPP 
participants alive at 1 September 2002 were eligible for the DPPOS. OGTT, oral glucose tolerance test. 
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Table S1. Formerly unexplored factors examined for their association with diabetes in the 
DPPOS. 
Table S2. Established factors examined for their association with diabetes in the DPPOS. 
Table S3. Formerly unexplored factors examined for their association with composite 
microvascular disease in the DPPOS. 
Table S4. Established factors examined for their association with composite microvascular 
disease in the DPPOS. 
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Table S5. Formerly unexplored factors examined for their association with  retinopathy, 
nephropathy and neuropathy in the DPPOS. 
Table S6. Established factors examined for their association with retinopathy, nephropathy 
and neuropathy in the DPPOS. 
 
 
Table 1. Established and formerly unexplored factors examined for their association with diabetes and/or 
microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS) 
Parameter Definitions Units 
Historical information 
h/o GDM History of gestational 
diabetes 
Y/N 
# comorbidities Number of comorbidites 
reported 
Number 
# meds used Number of medications 
used 
Number 
ADM Use of anti-depressant 
medications 
Y/N 
House income Annual household 
income 
per $10,000 
Amount of education  years 
# people in the home  Number 
Quality of life Based on SF6D Number 
Smoking Never/current/past  
Plasma measures 
Ever NGR Achieved 
normoglycaemia in 
Diabetes Prevention 
Program 
Number (%) 
Variability in HbA1c   
Fasting glucose  mg/dl 
2-hour glucose 2-hours post-OGTT mg/dl 
Proinsulin  pmol/l 
Adiponectin  g/ml 
C-reactive protein  mg/dl 
TG Triglycerides mg/dl 
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HDL High-density lipoprotein 
cholesterol 
mg/dl 
TG/HDL Ratio TG/HDL * 
CIR Index of insulin 
secretion 
pmol/l 
1/[insulin] Index of insulin 
sensitvity 
 
Metabolic measures 
BMI Body mass index kg/m
2
 
Waist circumference  cm 
Weight variability SD kg 
SBP Systolic blood pressure mmHg 
DBP Diastolic blood pressure mmHg 
Reported diet and 
activity 
  
Activity Leisure time physical 
activity 
MET/h/wk 
Total calories  kcal/day 
Servings of alcohol  #/day 
Calories from 
carbohydrate 
 % 
Calories from protein  % 
Calories from fat  % 
Established factors are in regular font, whereas unexplored factors are in italics. Values are taken from the 
baseline of the Diabetes Prevention Program (DPP), regression to normal glucose regulation (NGR) is defined 
during the DPP, and time-varying analyses across DPP and DPPOS were conducted for weight and HbA1c. 
*TG and HDL are both measured in mg/dl, so the ratio units cancel mathematically. 
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Table 2. Selected Known and Formerly Unexplored Factors Examined for their Association with Outcomes in 
the Diabetes Prevention Program Outcomes Study (DPPOS) 
Variable Diabetes MVD Retinopathy Nephropathy Neuropathy 
No. of 
comorbidities 
1.095 1.115 0.946 1.232 1.188 
No. of 
medications 
used 
1.073 1.100 1.021 1.158 1.190 
Variability in 
HbA1c 
1.020 1.064 1.091 1.037 1.091 
SBP 1.031 1.215 1.073 1.466 1.087 
DBP 0.998 1.135 1.062 1.313 0.983 
BMI 1.061 1.179 1.113 1.267 1.157 
Fasting glucose 1.199 1.029 1.086 0,079 1.034 
C-reactive 
protein 
0.983 1.095 1.132 1.048 1.142 
 
Numbers represent hazards ratio for diabetes and odds ratios for other outcomes in fully adjusted models. Each 
variable is adjusted for fasting plasma glucose, 2-hour glucose, HbA1c, BMI, hsitory of GDM (coefficient for 
GDM is the difference between females with GDM vs. females without GDM; coefficient for female is the 
difference between females without GDM vs. male), use of anti-depressant medication, ever NGR, adiponectin, 
CIR, 1/[insulin]. 
See Table 1 for descriptions of the variables shown in Table 2. Using the methods of Bonferroni, a P-value of 
≤ 0.002 was used to denote significance in order to account for multiple comparisons. Numbers in bold denote 
P ≤ 0.002. 
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